Background
Recent reports claim that about 38% of human breast cancers may contain sequences related to MMTV. Antibodies generated against mouse lymphoma cells that harbor the virus MMTV (mouse mammary tumor virus) were used to recognize human breast cancer. These antibodies can be used either in their current forms or in modified forms for diagnosis, prognosis, and subsequent treatment of certain human breast cancers. Working on proving correlation of appearance of p14 antibodies with human breast cancers Positive multi-sample trials will enable proof of p14 antibodies as diagnostic. correlation of appearance of p14 antibodies with human breast.
Our Innovation
Antibodies generated against mouse lymphoma cells that harbor MMTV recognize p14, the leader sequence (N-terminal peptide) of the precursor of the envelope protein of MMTV, and are used for immunohistochemical analysis of human breast cancers. Monoclonal antibodies to p14 can be subsequently humanized to treat breast cancer patients that express p14. Alternatively, P14 may be used as a vaccination against breast cancer.
The Applications for use:
-
Completely new approach to diagnosis and treatment of certain human breast cancers
-
Positive results already obtained in mice and in small number of human samples.
-
For the first time, there is a Possibility of development of vaccine against breast cancers containing MMTV .
